Introduction
HIV-1 strains can be assigned to M, O and N groups. Group M viruses are so far classified into 9 subtypes and at least 34 intersubtype circulating recombinant forms (CRFs). Although subtype B is the most frequent HIV-1 variant in Western countries, non-B clades are predominant in sub-Saharan Africa, where around 25 million of the 40 million people living with HIV are found. 1 Diagnostic tools and antiviral drugs for HIV-1 infection have been mainly designed based on subtype B. With a few exceptions, preliminary evidence suggests that most viral load assays and drug resistance methods are useful for testing specimens from distinct HIV-1 variants. 2 Antiretroviral therapy seems to be similarly effective in populations infected with distinct HIV-1 subtypes. 3 However, several in vitro studies have revealed that natural polymorphisms in non-B subtypes might compromise the Tel: þ34-91-4532500; Fax: þ34-91-7336614; E-mail: cmendoza@teleline.es effectiveness of individual drugs. Therefore, resistance interpretation algorithms have recently incorporated particular considerations for some non-B clades. 4 The current raised interest in the clinical and therapeutic implications of HIV-1 diversity is mainly derived from the major efforts that are being made to provide access to antiretroviral treatment in developing countries, as highlighted by the recently finished WHO '3 by 5' programme and the current 'Universal Access by 2010' programme. Moreover, there is increased awareness that expansion of HIV-1 non-B subtypes within Western regions is rapidly growing due to immigration and other population movements. 5 Thus, it is warranted to know to what extent current diagnostic tools and antiretroviral regimens perform in patients infected with non-B variants.
Patients and methods

Study population
All HIV-1-infected individuals on regular follow-up at one clinic located in Luanda, Angola, who had initiated triple antiretroviral therapy, were identified. For each of them, blood samples were collected on dried blood spots (DBS) after at least 6 months of therapy. DBS specimens were prepared applying a few drops of blood, freshly drawn by finger stick with a lancet, onto an absorbent specimen collection S&S903 filter paper (Schleicher & Schull, BioScience GmbH, Barcelona, Spain). The filters were left at room temperature overnight and stored at 48C in the absence of desiccant bags until shipment to Hospital Carlos III, Madrid, Spain. The study was approved by the Ethics Committee of the hospital and all participants signed a written informed consent.
Viral load
HIV-RNA was measured using the NucliSens EasyQ HIV-1 v1.1 (bioMérieux, Boxtel, The Netherlands), which has already proven to reliably measure viraemia for distinct HIV-1 variants both in plasma 6 and DBS. 7 
HIV subtyping and drug resistance
Nucleic acids present on DBS were isolated using the Boom method. In all viraemic patients, two different genomic regions of HIV-1 were amplified to determine HIV subtype and reverse transcriptase (RT) resistance mutations. The gp41 env region was amplified using previously described conditions. The RT region was amplified in a nested RT-PCR using as outer primers A35 (5 0 -TTG GTT GCA CTT TAA ATT TTC CCA TTA GTC CTA TT-3 0 ) and NE135 (5 0 -CTT ACT AAC TTC TGT ATG TCA TTG ACA GTC CAG CT-3 0 ), and as inner primers RTc1 (5 0 -ATG GAT GGY CCA AAR GTW AAA CAA TG-3 0 ) and RTc2 (5 0 -TGT CCA TTT YTC AGG ATG GAG YTC-3 0 ). Sequencing was performed using an automatic sequencer (ABI Prism 3100; Celera Diagnostics, Madrid, Spain) and electropherograms were analysed with SeqScape v2.5 (Applied Biosystems).
For HIV-1 subtyping, nucleotide sequences were aligned with reference strains of HIV-1 groups M, N and O (http://hiv-web.lanl. gov) using the CLUSTAL X method (MegAlign, Lasergene, DNASTAR Inc., Madison, WI, USA). Phylogenetic analyses were performed using the PHYLIP software package (version 3.5c; J. Felsenstein, University of Washington, Seattle, WA, USA).
Statistical analyses
Baseline characteristics of the study population are recorded as percentages, mean + standard deviations, or median values and 25% to 75% interquartile ranges (IQR). The Student t-test was used to compare quantitative variables, whereas the x 2 test was used to compare qualitative parameters. Differences were only considered significant when P values were below 0.05. All reported P values were two-sided.
Results
A total of 294 patients were examined. The main characteristics of this population are recorded in Table 1 . Some antiretroviral drugs were given in fixed pill combinations, such as Duovir or Combivir (zidovudine/lamivudine) and Triomune (stavudine/ lamivudine/nevirapine).
After a median of 12. A  M184V, T215NY  A98G, K101E, G190A  35  3TC, AZT, NVP  130 000  A  D67N, T69N, K70R, L74I, M184V, T215FI, K219E K101E, G190A  36  3TC, AZT, NVP  3300  B  M184V  K103N  38  3TC, AZT, NVP  9100  G  M184V  Y181C  39  3TC, AZT, NVP  8100  A  --40  3TC, AZT, NVP  7100  CRF01_AE  A62V, K70R, M184V  A98G, G190A  41  3TC, AZT, NVP  260 000  G  M41L, M184V, T215NY  A98G, K103N  43  3TC, AZT, NVP  490 000  CRF01_AE  M184V  K103, V108I, Y181C  44 3TC, AZT, NVP 410 000 CRF01_AE --a HIV-1 subtype was determined by phylogenetic analysis using a fragment of 650 nucleotides from the reverse transcriptase. NRTI, nucleoside reverse transcriptase inhibitors; NNRTI, non-nucleoside reverse transcriptase inhibitors; AZT, zidovudine; 3TC, lamivudine; NVP, nevirapine; EFV, efavirenz; d4T, stavudine. Genetic characterization of subtypes and drug resistance mutations could only be obtained in 45 out of 77 viraemic specimens (58.5%); this was not possible in the rest even after repeated attempts using different primers and PCR conditions. RT and gp41 sequences were obtained from 23 (30%) and 33 (43%) samples, respectively.
From the 23 RT sequences, mutation M184V was recognized in 15 and K103N in 9 cases. Other mutations such as T215F/Y, Y181C and G190A were seen in five patients each, and K70R and K101E in four patients ( Table 2 ). All viraemic patients but five harboured drug resistance mutations. HIV subtyping based on RT sequences was as follows: 4 A (17.4%), 3 C (13%), 2 B (8.7%), 2 F (8.7%), 2 G (8.7%), 2 H (8.7%), 4 CRF01_AE (17.4%), 2 CFR14_BG (8.7%), 1 CRF02_AG (4.3%) and 1 CRF13/CRF11 (4.3%).
The gp41 region could be sequenced in 33 (43%) of 77 viraemic patients. One patient harboured mutation S138A, which has been associated with enfuvirtide resistance, and 14 harboured the N42S polymorphism. Eleven different HIV-1 variants could be identified based on gp41 sequences, including 6 clade C (18.2%), 2 F (6%), 2 H (6%), 1 D (3%), 1 G (3%), 8 CRF02_AG (24.2%), 2 CRF06 (6%), 1 CRF01_AE (3%), 1 CRF14_BG (3%), 1 CRF25 (3%) and 1 CRF19 (3%). For 7 (21%) subtyping was undetermined.
Discussion
Several studies have suggested that differences may exist between distinct HIV-1 subtypes in disease progression and, at least in vitro, susceptibility to antiretroviral drugs. 4 These aspects have acquired particular relevance given the growing introduction of antiretroviral therapy in developing countries and because of the increased circulation of non-B subtypes in Western regions. 8 In this cross-sectional study, the rate of virological suppression inferred from testing on DBS was 74%, which may be regarded as satisfactory. The lack of baseline specimens precluded determination of the individual benefit of therapy and represents a limitation of this study. Drug resistance mutations in the RT gene emerged at the same positions and apparently at similar rates as in clade B viruses. Not surprisingly M184V and K103N were the most frequent changes, as they rapidly appear following lamivudine and nevirapine/efavirenz failure, respectively. In addition, CD4 gains were significantly greater in virological responders than in viraemic patients. Altogether, these results suggest that antiretroviral therapy may be equally effective in patients infected with non-B subtypes and living in developing regions as in persons infected with clade B viruses and treated in Western countries. This is in agreement with other recent reports from Senegal, Uganda and Kenya 3 and provides strong evidence for encouraging the use of antiretroviral therapy in resource-limited settings.
Patients experiencing virological failure of antiretroviral therapy in our study underwent further virological characterization. The high HIV-1 genetic variability we recognized in Angola has already been noted by others. 9 This is consistent with the close geographical proximity to Cameroon, where the postulated origin of HIV-1 took place around 70 years ago.
However, adequate genetic amplicons could only be obtained from half of viraemic specimens. It is important to determine the reasons for this poor success rate. First, the high HIV-1 genetic diversity might compromise primer binding, even when they were designed based on highly conserved regions of the pol gene. Second, and most important, we learned later that no special control of humidity using dessiccant bags was taken during storage, although the protocol dictated preservation at 48C. While short DNA/RNA fragments are less likely to be affected by degradation, and therefore may impact less on viral load measurements, the longer nucleic acid fragments required for sequencing may be badly affected. Conditions for DBS preservation, especially humidity, may have a large impact on the degradation of nucleic acids. 10 We could not find any relationship between any specific HIV-1 subtype and emergence of signature drug resistance mutations, although the limited size of the study population failing antiretroviral therapy precluded examination of this aspect in more detail. Information on prior use of nevirapine in pregnant women or baseline resistance was not available. This information might be relevant since 70% of the study population were women and information derived from mother-to-child prevention trials have already underlined that either Y181C or K103N are the main changes emerging following single-dose nevirapine exposure in non-B subtypes.
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In summary, the virological response to NNRTI-based triple regimens assessed using DBS specimens seems to be similar in Angola to that in Western countries, despite the large HIV-1 subtype heterogeneity. DBS may be a useful tool for collecting and shipping blood for testing in adequate facilities, as it does not require rigorous storage conditions nor does it represent a potential source of infectious material. However, adequate storage conditions, including control of humidity, are warranted to ensure success of nucleic acid amplification procedures.
